Home › Graft-Versus-Host Disease › New Jersey › Edison
Graft-Versus-Host Disease clinical trials in Edison, NJ
4 studies for Graft-Versus-Host Disease are looking for participants at sites in and around Edison (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of LBP-MARCO and Ruxolitinib in People With Graft-Versus-Host Disease (GVHD)
RecruitingPhase 1
- Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge · 15 mi away
A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
RecruitingPhase 2
- Memorial Sloan Kettering at Basking Ridge (Consent only), Basking Ridge · 15 mi away
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
RecruitingPhase 2
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge · 15 mi away
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
RecruitingPhase 2
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge · 15 mi away
Graft-Versus-Host Disease trials in other cities
- Boston, MA9 studies
- New York City, NY8 studies
- Columbus, OH6 studies
- Queens, NY6 studies
- Washington, DC5 studies
- Atlanta, GA5 studies
- Baldwin Park, CA5 studies
- Miami, FL4 studies
- Tampa, FL4 studies
- Portland, OR4 studies
- Detroit, MI4 studies
- Houston, TX4 studies
Other studies in Edison
- Breast Cancer70 studies
- Non-Small Cell Lung Cancer50 studies
- Cancer (all types)33 studies
- Prostate Cancer29 studies
- Colorectal Cancer25 studies
- Lung Cancer25 studies
- Bladder Cancer23 studies
- Multiple Myeloma21 studies
- Metastatic Cancer20 studies
- Endometrial Cancer20 studies
- Acute Myeloid Leukemia20 studies
- Ovarian Cancer19 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.